Project Grant R43AI140856

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $185,513 to Tulane University to develop a multivalent subunit vaccine against enterotoxigenic Escherichia coli (ETEC), a major cause of diarrheal disease in children in low-resource settings. The research aims to establish protective immunity in the gastrointestinal tract by testing the ability of outer...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $242,058 to George Washington University to plan a clinical trial testing the efficacy of the NA-GST-1 hookworm vaccine candidate. The goal is to assess the vaccine's ability to provide protection against hookworm infection using a controlled human infection model (CHIM). The award will fund activities to prepare for...

This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and evaluate a novel multi-epitope protease cleavage sites (MEPCS) vaccine for protecting against SIV (Simian Immunodeficiency Virus) rectal transmission. The $650,156 award, effective August 21, 2024 through June 30, 2029, will support comparative evaluations of a cold-chain friendly and long-term stable...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $400,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Baylor College of Medicine in Houston, Texas. The funding will support pre-clinical studies to test the prophylactic efficacy of a potential vaccine against extraintestinal pathogenic E. coli (ExPEC), a member of the human microbiome that has become a leading cause of antibiotic-resistant mortality worldwide. The research...

The University of Delaware was awarded a $2,812,558 Trans-NIH Research Support Project Grant from the National Institutes of Health Office of the Director to develop an oral vaccine delivery platform utilizing nitrated bacterial antigens displayed on Bacillus subtilis spores. The three-year project aims to advance the understanding of how nitration can enhance the immunogenicity of weakly immunogenic bacterial antigens from pathogens like Shigella. Researchers will perform animal studies using...

This $1,397,469 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to identify correlates of protection against cholera, which are measures of immunity that can predict effectiveness of cholera vaccines. The 5-year study will follow cohorts of cholera vaccine recipients and individuals with natural cholera infection to compare immune responses and determine which markers accurately predict subsequent...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $798,173 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University to develop novel multivalent mucosal vaccines for human noroviruses. The goal is to generate live-vectored mucosal vaccines using the FDA-approved rotavirus (RotaTeq) and measles/mumps/rubella (MMR) vaccine platforms to induce strong systemic and mucosal immune responses that provide broad...

This $2,002,422 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of systemic and mucosal immunity to vaccination and infection with enteric bacterial pathogens like Salmonella and Shigella in children and adults. The research will use human-based models and specimens from clinical studies to examine the mechanisms underlying...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $997,318.00 to Northwestern University to evaluate whether vaccine fractionation, using reduced priming doses followed by standard boosting doses, can improve the immunogenicity and efficacy of HIV vaccines across different vaccine platforms including adenovirus-based and mRNA-based vaccines. The research will be...